EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐ PD ‐1 immunotherapy in head and neck cancer

Mei-Chun Lin, Ya-Ting Chuang, Hsin-Yi Wu, Chia-Lang Hsu, Neng-Yu Lin, Min-Chuan Huang iD, Pei-Jen Lou iD

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Mei-Chun Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Interleukin-6, Head and Neck Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Health Research Institutes, Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine and National Taiwan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cells in the tumor microenvironment (TME) communicate via membrane‐bound and secreted proteins, which are mostly glycosylated. Altered glycomes of malignant tumors influence behaviors of stromal cells. In this study, we showed that the loss of core‐1 β1,3‐galactosyltransferase (C1GALT1)‐mediated O‐glycosylation suppressed tumor growth in syngeneic head and neck cancer mouse models. O‐glycan truncation in tumor cells promoted the M1 polarization of macrophages, enhanced T‐cell‐mediated cytotoxicity, and reduced interleukin‐6 (IL‐6) levels in the secretome. Proteasomal degradation of IL‐6 was controlled by the O‐glycan at threonine 166. Both IL‐6/IL‐6R blockade and O‐glycan truncation in tumor cells induced similar pro‐inflammatory phenotypes in macrophages and cytotoxic T lymphocytes (CTLs). The combination of the O‐glycosylation inhibitor itraconazole and anti‐programmed cell death protein 1 (anti‐PD‐1) antibody effectively suppressed tumor growth in vivo . Collectively, our findings demonstrate that O‐glycosylation in tumor cells governs their crosstalk with macrophages and CTLs. Thus, targeting O‐glycosylation successfully reshapes the TME and consequently enhances the efficacy of anti‐PD‐1 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6Head and Neck NeoplasmsAnimalsMiceGlycosylationCell Line, TumorImmunotherapyPolysaccharidesTumor Microenvironment

Stichwörter der Autor:innen

IL-6O-glycosylationcore 1 β1,3-galactosyltransferasehead and neck cancerimmune checkpoint inhibitoritraconazole

Substanzen

Interleukin-6Polysaccharides

Autor:innen und Institutionen

  • Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
  • Instrumentation Center, National Taiwan University, Taipei, Taiwan.
  • Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan.

ORCID-Profile: Min-Chuan Huang, Pei-Jen Lou

Förderung

  • Ministry of Science and Technology, Taiwan
  • National Health Research Institutes
  • Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine and National Taiwan University

Zitieren

APA

Lin, M. C., Chuang, Y. T., Wu, H. Y., Hsu, C. L., Lin, N. Y., Huang, M. C., & Lou, P. J. (2024). Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐ PD ‐1 immunotherapy in head and neck cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13489

Vancouver

Lin MC, Chuang YT, Wu HY, Hsu CL, Lin NY, Huang MC, et al. Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐ PD ‐1 immunotherapy in head and neck cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13489

BibTeX
@article{Lin2024,
  author = {Lin, Mei-Chun and Chuang, Ya-Ting and Wu, Hsin-Yi and Hsu, Chia-Lang and Lin, Neng-Yu and Huang, Min-Chuan and Lou, Pei-Jen},
  title = {Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐ PD ‐1 immunotherapy in head and neck cancer},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13489}
}
Kostenlos starten →